Advertisement

Relevance of anti-HNK1 antibodies in the management of anti-MAG neuropathies

  • Emilien DelmontEmail author
  • Shahram Attarian
  • Jean-Christophe Antoine
  • Stephane Paul
  • Jean Philippe Camdessanché
  • Aude-Marie Grapperon
  • Alexandre Brodovich
  • Jose Boucraut
Original Communication
  • 29 Downloads

Abstract

Introduction

In peripheral neuropathies with antibodies against Myelin Associated Glycoprotein (MAG), an IgM monoclonal gammopathy recognizes a specific epitope called Human Natural Killer 1 (HNK1) shared by NK lymphocytes and several components of the peripheral nerve myelin. Recently an ELISA test has been developed to detect antibodies against HNK1 epitope. Objectives were to determine the usefulness of this assay in the management of anti-MAG neuropathy.

Methods

Anti-HNK1 antibodies were assessed with the GanglioCombi™ MAG ELISA test (Buhlmann) in 41 anti-MAG neuropathies and in 118 controls: 34 chronic inflammatory demyelinating polyradiculoneuropathies, 3 Miller Fisher syndromes, 12 sensory neuronopathies, 63 length-dependent axonal sensory polyneuropathies, 6 healthy controls. Anti-HNK1 antibody was tested before and 1 year after rituximab therapy in seven patients with anti-MAG neuropathy.

Results

Anti-HNK1 antibodies were positive in 40/41 anti-MAG neuropathies, and in 1/118 controls (sensitivity 98%, specificity 99%). Only considering controls with IgM paraprotein, specificity was 96% (23/24). In anti-MAG neuropathies, anti-HNK1 titre was correlated with sensory deficiency evaluated with the INCAT sensory sum score (r = 0.4, p = 0.01) and with disability evaluated with the Rasch-built Overall Disability Scale (r = \(-\) 0.4, p = 0.01) and Overall Neuropathy Limitation Scale (r = 0.4, p = 0.02). Anti-HNK1 titres were not related to age, disease duration, atypical clinical features and anti-MAG antibodies titres. Anti-MAG titres were not associated with disease severity. Anti-HNK1 titres were decreased by 18% 1 year after rituximab treatment.

Conclusions

Anti-HNK1 antibodies have good sensitivity and specificity for the diagnosis of anti-MAG neuropathy. Interestingly, anti-HNK1 titres are related to the disease severity and decrease after rituximab infusions.

Keywords

Anti-MAG antibodies Anti-HNK1 antibodies Peripheral neuropathy Biomarker 

Notes

Compliance with ethical standards

Conflicts of interest

The author declares that there is no competing interest.

Ethical standards

This study was in compliance with the ethical principles of the conference of Helsinki.

References

  1. 1.
    Joint Task Force of the EFNS and the PNS (2010) European Federation of Neurological Societies/Peripheral Nerve Society Guideline on management of paraproteinemic demyelinating neuropathies. J Peripher nerv Syst 15:185–195CrossRefGoogle Scholar
  2. 2.
    Svahn J, Petiot P, Antoine J-C et al (2017) Anti-MAG antibodies in 202 patients: clinicopathological and therapeutic features. J Neurol Neurosurg Psychiatry.  https://doi.org/10.1136/jnnp-2017-316715 Google Scholar
  3. 3.
    Gazzola S, Delmont E, Franques J et al (2017) Predictive factors of efficacy of rituximab in patients with anti-MAG neuropathy. J Neurol Sci.  https://doi.org/10.1016/j.jns.2017.04.015 Google Scholar
  4. 4.
    Magy L, Kaboré R, Mathis S et al (2015) Heterogeneity of polyneuropathy associated with anti-MAG antibodies. J Immunol Res 2015:450391.  https://doi.org/10.1155/2015/450391 CrossRefGoogle Scholar
  5. 5.
    Nobile-Orazio E, Meucci N, Baldini L et al (2000) Long-term prognosis of neuropathy associated with anti-MAG IgM M-proteins and its relationship to immune therapies. Brain 123(Pt 4):710–717CrossRefGoogle Scholar
  6. 6.
    Delmont E, Hiew FL, Cassereau J et al (2017) Determinants of health-related quality of life in anti-MAG neuropathy: a cross-sectional multicentre European study. J Peripher Nerv Syst 22:27–33.  https://doi.org/10.1111/jns.12197 CrossRefGoogle Scholar
  7. 7.
    Attarian S, Azulay JP, Boucraut J et al (2001) terminal latency index and modified F ratio in distinction of chronic demyelinating neuropathies. Clin Neurophysiol 112:457–463CrossRefGoogle Scholar
  8. 8.
    Lunn MP, Nobile-Orazio E (2016) Immunotherapy for IgM anti-myelin-associated glycoprotein paraprotein-associated peripheral neuropathies. Cochrane Database Syst Rev 22:22.  https://doi.org/10.1002/14651858.CD002827.pub4 Google Scholar
  9. 9.
    Gazzola S, Delmont E, Franques J et al (2017) Predictive factors of efficacy of rituximab in patients with anti-MAG neuropathy. J Neurol Sci 377:144–148.  https://doi.org/10.1016/j.jns.2017.04.015 CrossRefGoogle Scholar
  10. 10.
    Kuijf ML, Eurelings M, Tio-Gillen AP et al (2009) Detection of anti-MAG antibodies in polyneuropathy associated with IgM monoclonal gammopathy. Neurology 73:688–695.  https://doi.org/10.1212/WNL.0b013e3181b59a80 CrossRefGoogle Scholar
  11. 11.
    Caudie C, Kaygisiz F, Jaquet P et al (2006) Diagnostic value of autoantibodies to MAG by ELISA Bühlmann in 117 immune-mediated peripheral neuropathies associated with monoclonal IgM to SGPG/SGLPG. Ann Biol Clin (Paris) 64:353–359Google Scholar
  12. 12.
    Hamada Y, Hirano M, Kuwahara M et al (2014) Binding specificity of anti-HNK-1 IgM M-protein in anti-MAG neuropathy: possible clinical relevance. Neurosci Res 22:22.  https://doi.org/10.1016/j.neures.2014.09.010 Google Scholar
  13. 13.
    McGarry RC, Helfand SL, Quarles RH, Roder JC (1983) Recognition of myelin-associated glycoprotein by the monoclonal antibody HNK-1. Nature 306:376–378CrossRefGoogle Scholar
  14. 14.
    Van Den Berg LH, Sadiq SA, Thomas FP, Latov N (1990) Characterization of HNK1 bearing glycoproteins in human peripheral nerve myelin. J Neurosci Res 25:295–299.  https://doi.org/10.1002/jnr.490250305 CrossRefGoogle Scholar
  15. 15.
    Morise J, Takematsu H, Oka S (2017) The role of human natural killer-1 (HNK-1) carbohydrate in neuronal plasticity and disease. Biochim Biophys Acta Gen Subj 1861:2455–2461.  https://doi.org/10.1016/j.bbagen.2017.06.025 CrossRefGoogle Scholar
  16. 16.
    Herrendorff R, Hänggi P, Pfister H et al (2017) Selective in vivo removal of pathogenic anti-MAG autoantibodies, an antigen-specific treatment option for anti-MAG neuropathy. Proc Natl Acad Sci 114:E3689–E3698.  https://doi.org/10.1073/pnas.1619386114 CrossRefGoogle Scholar
  17. 17.
    Merkies ISJ, Schmitz PIM, van der Meché FGA et al (2002) Clinimetric evaluation of a new overall disability scale in immune mediated polyneuropathies. J Neurol Neurosurg Psychiatry 72:596–601.  https://doi.org/10.1136/jnnp.72.5.596 CrossRefGoogle Scholar
  18. 18.
    Graham RC, Hughes RAC (2006) A modified peripheral neuropathy scale: the Overall Neuropathy Limitations Scale. J Neurol Neurosurg Psychiatry 77:973–976CrossRefGoogle Scholar
  19. 19.
    Van Nes SI, Vanhoutte EK, Van Doorn PA et al (2011) Rasch-built Overall Disability Scale (R-ODS) for immune-mediated peripheral neuropathies. Neurology 76:337–345.  https://doi.org/10.1212/WNL.0b013e318208824b CrossRefGoogle Scholar
  20. 20.
    Léger J-M, Viala K, Nicolas G et al (2013) Placebo-controlled trial of rituximab in IgM anti-myelin-associated glycoprotein neuropathy. Neurology 80:2217–2225CrossRefGoogle Scholar
  21. 21.
    Delmont E, Manso C, Querol L et al (2017) Autoantibodies to nodal isoforms of neurofascin in chronic inflammatory demyelinating polyneuropathy. Brain 140:1851–1858.  https://doi.org/10.1093/brain/awx124 CrossRefGoogle Scholar
  22. 22.
    Willison HJ, O’Leary CP, Veitch J et al (2001) The clinical and laboratory features of chronic sensory ataxic neuropathy with anti-disialosyl IgM antibodies. Brain 124:1968–1977CrossRefGoogle Scholar
  23. 23.
    Lim JP, Devaux J, Yuki N (2014) Peripheral nerve proteins as potential autoantigens in acute and chronic inflammatory demyelinating polyneuropathies. Autoimmun Rev 13:1070–1078.  https://doi.org/10.1016/j.autrev.2014.08.005 CrossRefGoogle Scholar
  24. 24.
    Roggenbuck JJ, Boucraut J, Delmont E et al (2018) Diagnostic insights into chronic-inflammatory demyelinating polyneuropathies. Ann Transl Med.  https://doi.org/10.21037/atm.2018.07.34 Google Scholar
  25. 25.
    Sakamoto Y, Shimizu T, Tobisawa S, Isozaki E (2017) Chronic demyelinating neuropathy with anti-myelin-associated glycoprotein antibody without any detectable M-protein. Neurol Sci 38:2165–2169.  https://doi.org/10.1007/s10072-017-3133-0 CrossRefGoogle Scholar
  26. 26.
    Dobersen MJ, Hammer JA, Noronha AB et al (1985) Generation and characterization of mouse monoclonal antibodies to the myelin-associated glycoprotein (MAG). Neurochem Res 10:499–513CrossRefGoogle Scholar
  27. 27.
    Dalakas MC, Rakocevic G, Salajegheh M et al (2009) Placebo-controlled trial of rituximab in IgM anti-myelin-associated glycoprotein antibody demyelinating neuropathy. Ann Neurol 65:286–293CrossRefGoogle Scholar
  28. 28.
    Renaud S, Gregor M, Fuhr P et al (2003) Rituximab in the treatment of polyneuropathy associated with anti-MAG antibodies. Muscle Nerve 27:611–615CrossRefGoogle Scholar
  29. 29.
    Benedetti L, Briani C, Grandis M et al (2007) Predictors of response to rituximab in patients with neuropathy and anti-myelin associated glycoprotein immunoglobulin M. J Peripher Nerv Syst 12:102–107CrossRefGoogle Scholar

Copyright information

© Springer-Verlag GmbH Germany, part of Springer Nature 2019

Authors and Affiliations

  • Emilien Delmont
    • 1
    Email author
  • Shahram Attarian
    • 1
  • Jean-Christophe Antoine
    • 2
  • Stephane Paul
    • 3
  • Jean Philippe Camdessanché
    • 2
  • Aude-Marie Grapperon
    • 1
  • Alexandre Brodovich
    • 1
    • 4
  • Jose Boucraut
    • 4
  1. 1.Referral Centre for ALS and Neuromuscular DiseasesMarseilleFrance
  2. 2.Department of Neurology and Referral Centre for Neuromuscular DiseasesSaint EtienneFrance
  3. 3.Immunology LaboratorySaint EtienneFrance
  4. 4.Immunology LaboratoryMarseilleFrance

Personalised recommendations